Tech and Pharma Giants Invest Billions in AI Drug Discovery Amid Cautious Outlook

Technology companies and pharmaceutical firms are pouring billions into artificial intelligence partnerships to accelerate drug discovery, but early clinical data reveals the field has yet to solve its most fundamental challenge: predicting whether molecules actually work in patients. In 2026, the sector has seen an unprecedented wave of strategic collaborations, with major deals announced almost monthly. Merck committed $1 billion to a multiyear partnership with Google Cloud in April, deploying Gemini Enterprise across its research, manufacturing, and commercial operations. Eli Lilly and NVIDIA jointly announced a $1 billion co-innovation lab focused on AI-driven drug discovery, expected to open in San Francisco in late March. Meanwhile, Novo Nordisk has integrated OpenAI's capabilities across its operations, including the GPT-Rosalind model designed specifically for biology and drug discovery research. In May, Isomorphic Labs—backed by Alphabet and other investors—raised $2.1 billion in Series B funding, one of the largest financings for an AI-first biotech company, with partnerships anchored by Novartis, Eli Lilly, and Johnson & Johnson. The global market for AI in drug discovery reached $3.1 billion in 2025 and is projected to grow at 30.5% annually through 2035, driven by collaboration between tech hyperscalers and established pharma seeking to modernize research workflows.